Abstract 4CPS-075 Table 1
Patients without IRAF
=23
(85.2%)
Patients with IRAFN
=5
(17.8%)
Age (years)
73±11
75±6
Sex (M/F)
12/11
4/1
Previously AF (n (%))
1 (4.4)
1 (20)
Indication LLC (n (%))
20 (86.9)
4 (80.0)
Ibrutinib duration (months)
13.7±11.2
18.6±9.7